C07D 249/08
1,2,4-triazoles
Official title: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
C07D249/08 (1,2,4-triazoles) appears on 6,203 US grants and 3,100 published applications in this corpus.
Search patents in C07D- Granted patents
- 6,203
- Published applications
- 3,100
- Assignees
- 1,461
- Inventors
- 12,607
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 76 | 0 |
| 1977 | 79 | 0 |
| 1978 | 93 | 0 |
| 1979 | 71 | 0 |
| 1980 | 92 | 0 |
| 1981 | 107 | 0 |
| 1982 | 98 | 0 |
| 1983 | 104 | 0 |
| 1984 | 105 | 0 |
| 1985 | 144 | 0 |
| 1986 | 156 | 0 |
| 1987 | 135 | 0 |
| 1988 | 163 | 0 |
| 1989 | 199 | 0 |
| 1990 | 222 | 0 |
| 1991 | 202 | 0 |
| 1992 | 215 | 0 |
| 1993 | 196 | 0 |
| 1994 | 153 | 0 |
| 1995 | 153 | 0 |
| 1996 | 169 | 0 |
| 1997 | 179 | 0 |
| 1998 | 173 | 0 |
| 1999 | 171 | 0 |
| 2000 | 154 | 0 |
| 2001 | 173 | 37 |
| 2002 | 207 | 167 |
| 2003 | 190 | 260 |
| 2004 | 123 | 297 |
| 2005 | 136 | 187 |
| 2006 | 153 | 147 |
| 2007 | 119 | 127 |
| 2008 | 87 | 117 |
| 2009 | 86 | 120 |
| 2010 | 108 | 129 |
| 2011 | 90 | 124 |
| 2012 | 100 | 98 |
| 2013 | 86 | 101 |
| 2014 | 98 | 148 |
| 2015 | 110 | 122 |
| 2016 | 94 | 131 |
| 2017 | 108 | 117 |
| 2018 | 80 | 97 |
| 2019 | 73 | 79 |
| 2020 | 78 | 98 |
| 2021 | 75 | 86 |
| 2022 | 46 | 73 |
| 2023 | 54 | 73 |
| 2024 | 49 | 67 |
| 2025 | 42 | 60 |
| 2026 | 29 | 38 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- NAMPT modulators29 Sep 2026US 12,747,203 B2Cytokinetics, Inc.
- Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents22 Sep 2026US 12,740,943 B2ModernaTX, Inc.
- Lipoxygenase inhibitors22 Sep 2026US 12,741,926 B2SRI International
- Ferroptosis inhibitors—diarylamine para-acetamides25 Aug 2026US 12,715,855 B2Sironax Ltd.
- Agrochemical composition11 Aug 2026US 12,702,133 B2Upl Ltd
- Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xpo1 inhibitors8 Oct 2026US 2026/0308132 A1Karyopharm Therapeutics Inc.
- 3,5-diaminotriazole derivatives and uses thereof for treating ocular diseases24 Sep 2026US 2026/0284014 A1Centre National De La Recherche Scientifique
- Inhibitors of myc and uses thereof17 Sep 2026US 2026/0274827 A1Northwestern University
- Method for producing 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol27 Aug 2026US 2026/0250253 A1BASF Agro B.V.
- At2 antagonists for non-addictive pain relief20 Aug 2026US 2026/0242357 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Pyrrolidine-containing monomers and oligomers675US 5,519,134 AIsis Pharmaceuticals, Inc. · 1996
- Alkynyl and azido-substituted 4-anilinoquinazolines379US 5,747,498 APfizer Inc. · 1998
- Substituted biphenyl isoxazole sulfonamides222US 5,612,359 ABristol-Myers Squibb Company · 1997
- Nitrogen containing heteroaromatics as factor Xa inhibitors211US 6,020,357 ADuPont Pharmaceuticals Company · 2000
- Pyrimidine-5-carboxamide derivatives185US 6,432,963 B1Yamanouchi Pharmaceutical Co., Ltd. · 2002